Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
1/17/25 Novo Nordisk (NVO) Wegovy for Obesity Subscribers Only Subscribers Only Subscribers Only
1/16/25 Boehringer BI-425809 for Schizophrenia Subscribers Only Subscribers Only Subscribers Only
1/15/25 OS Therapies (OSTX) OST-HER2 for Osteosarcoma Subscribers Only Subscribers Only Subscribers Only
1/14/25 Sling Therapeutics Linsitinib for Thyroid Eye Disease (TED) Subscribers Only Subscribers Only Subscribers Only
1/14/25 Immuron (IMC) Travelan for Gastroenteritis Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
09/12/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/16/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/30/2024 Subscribers Only Subscribers Only Progress Update - Development Review
11/15/2024 Subscribers Only Subscribers Only Partnership - Acquisition Completion
11/19/2024 Subscribers Only Subscribers Only Partnership - Acquisition Completion